Pimasertib (MSC1936369B/AS703026), a Selective Oral MEK1/2 Inhibitor, Shows Clinical Activity in Melanoma

J. P. Delord, N. Houede, A. Awada, C. Lebbe, T. Lesimple, J. H. M. Schellens, S. Rottey, R. Kefford, N. Rejeb, E. Raymond

Research output: Contribution to journalMeeting abstractpeer-review

Original languageEnglish
Article number616
Pages (from-to)190-190
Number of pages1
JournalEuropean Journal of Cancer
Volume48
DOIs
Publication statusPublished - Nov 2012
Externally publishedYes
Event24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Dublin, Ireland
Duration: 6 Nov 20129 Nov 2012

Cite this